Shows improved anticoagulation with two-stage citrate protocol in heparin-free intermittent hemodialysis, indicating safety for patients with high bleeding risk.
Abstract In recent years, due to the low risk of bleeding, regional citrate anticoagulation (RCA) is being tried for intermittent hemodialysis (IHD). Simplified regional citrate anticoagulation (S-RCA) has been attempted in IHD. This randomized cross-over trial was designed to compared the efficacy and safety of two RCAs in heparin-free dialysis patients, which were named S-RCA and two-stage simplified regional citrate anticoagulation (TS-RCA). In summary, the anticoagulation effect of TS-RCA is better than that of S-RCA in IHD, especially in the anticoagulation of venous bubbles trap. And these two RCAs were safe for IHD patient with high bleeding risk. Trial Registration: Chinese Clinical Trial Registry (CHICTR): Registration Number ChiCTR2000034314; Registration date 28 September 2020.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: